Skip to content

Kite Pharma, Inc.

Delisted

CIK 1510580fmd_0A0PB25HW1MWGTB1QM2F4YBM11Manufacturing · Biological Products, (No Diagnostic Substances)Template: Standard

Coverage: Jan 01, 2012 to Jun 30, 2017, 19 periods

Latest annual · FY2016

Millions
Total revenues
22
Operating income
(273)
Net income
(267)
Free cash flow
(189)

Latest quarter · Q2 FY2017

Millions
Total revenues
10
Operating income
(102)
Net income
(110)
Free cash flow
(38)
Open Financials

Key stats

Open Analysis

Compound annual growth

Revenue, 3 yearsFY2013 to FY2016
n/m

Kite Pharma, Inc. financials: quick answers

Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.

MetricFY2016FY2015ChangeSource
Revenue$22.2 million$17.3 million+28.5%10-K 2017-02-28 · proof
Operating income-$273.2 million-$104 million10-K 2017-02-28 · proof
Net income-$267.1 million-$101.7 million10-K 2017-02-28 · proof
Cash from operating activities-$168.9 million-$19 million10-K 2017-02-28 · proof
Free cash flow-$189.1 million-$45.6 million10-K 2017-02-28 · proof
Total assets$524.3 million$708 million-25.9%10-K 2017-02-28 · proof
Total liabilities$96.3 million$92.2 million+4.5%10-K 2017-02-28 · proof
Cash and cash equivalents$114.6 million$392.8 million-70.8%10-K 2017-02-28 · proof
What was Kite Pharma, Inc.'s revenue in fiscal 2016?
Kite Pharma, Inc. reported revenue of $22.2 million for fiscal 2016 (the year ended Dec 31, 2016), against $17.3 million the year before (+28.5%). Source: the 10-K filed with the SEC on Feb 28, 2017. SEC
What was Kite Pharma, Inc.'s operating income in fiscal 2016?
Kite Pharma, Inc. reported operating income of -$273.2 million for fiscal 2016 (the year ended Dec 31, 2016), against -$104 million the year before. Source: the 10-K filed with the SEC on Feb 28, 2017. SEC
What was Kite Pharma, Inc.'s net income in fiscal 2016?
Kite Pharma, Inc. reported net income of -$267.1 million for fiscal 2016 (the year ended Dec 31, 2016), against -$101.7 million the year before. Source: the 10-K filed with the SEC on Feb 28, 2017. SEC
What was Kite Pharma, Inc.'s cash from operating activities in fiscal 2016?
Kite Pharma, Inc. reported cash from operating activities of -$168.9 million for fiscal 2016 (the year ended Dec 31, 2016), against -$19 million the year before. Source: the 10-K filed with the SEC on Feb 28, 2017. SEC
What was Kite Pharma, Inc.'s free cash flow in fiscal 2016?
Kite Pharma, Inc. reported free cash flow of -$189.1 million for fiscal 2016 (the year ended Dec 31, 2016), against -$45.6 million the year before. Source: the 10-K filed with the SEC on Feb 28, 2017. SEC
What are Kite Pharma, Inc.'s total assets?
As of Dec 31, 2016, Kite Pharma, Inc. reported total assets of $524.3 million, against $708 million a year earlier (-25.9%). Source: the 10-K filed with the SEC on Feb 28, 2017. SEC
What are Kite Pharma, Inc.'s total liabilities?
As of Dec 31, 2016, Kite Pharma, Inc. reported total liabilities of $96.3 million, against $92.2 million a year earlier (+4.5%). Source: the 10-K filed with the SEC on Feb 28, 2017. SEC
What are Kite Pharma, Inc.'s cash and cash equivalents?
As of Dec 31, 2016, Kite Pharma, Inc. reported cash and cash equivalents of $114.6 million, against $392.8 million a year earlier (-70.8%). Source: the 10-K filed with the SEC on Feb 28, 2017. SEC

Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.

The same numbers for an agent, with proof on every value:

curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1510580&period_type=annual&limit=5"

Information only, not investment advice.